Medtronic has launched the new CE marked Resolute Integrity drug eluting stent for the European market. The device is meant to provide easier navigation through vasculature thanks to implementation of “continuous sinusoid technology.”
Based on the engineering advance of continuous sinusoid technology, the Resolute Integrity Stent System has been shown in bench testing and in blinded in vivo physician assessment studies to be significantly more deliverable than the current market-leading alternatives.
Coupled with the MicroTrac delivery system, continuous sinusoid technology improves deliverability without compromising other important stent design characteristics like radial strength. It also improves the stent’s conformability – the ability of the stent to conform to the natural shape of the vessel and maintain apposition to the vessel wall after inflation with the balloon catheter.
The Resolute Integrity drug-eluting stent (DES) combines continuous sinusoid technology with two key elements of the original Resolute DES: the cytostatic antiproliferative drug zotarolimus and the highly biocompatible BioLinx polymer.
Press release: Medtronic Launches Resolute Integrity Drug-Eluting Stent In Europe …